| INTRODUCTION
Hypoadrenocorticism is an endocrine disorder that results in a deficiency of glucocorticoids and, in most cases, mineralocorticoids.
Hypoadrenocorticism can be a result of primary adrenal failure or can be secondary to pituitary dysfunction and subsequent decreased or absent ACTH secretion. 1 Although the disease is fairly uncommon, testing for hypoadrenocorticism occurs relatively frequently because of the nonspecific signs and potential serious complications associated with a missed diagnosis. Definitive diagnosis is obtained by performing an ACTH stimulation test, an expensive procedure that may not be carried out because of financial concerns of owners. In an effort to decrease cost associated with the diagnosis of hypoadrenocorticism, several laboratory, and imaging abnormalities have been investigated for their diagnostic utility. Variables that have been investigated include leukogram changes, sodium-to-potassium ratio, basal serum cortisol concentrations, serum aldosterone concentrations, cortisol-to-ACTH ratio, aldosterone-to-renin ratio, and size of the adrenal glands as measured by ultrasound examination. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Despite extensive research, definitive diagnosis of hypoadrenocorticism still cannot be reliably made without an ACTH stimulation test. In addition, performance of multiple screening tests in a patient ultimately may result in high cost and a delay in definitive diagnosis.
Use of a lower cosyntropin dose could decrease cost associated with ACTH stimulation testing. In healthy dogs, a 1 μg/kg dose of cosyntropin stimulates maximal adrenocortical cortisol secretion. 12 The lower 1 μg/kg dose has been evaluated in dogs suspected of or treated for hyperadrenocorticism, but, to our knowledge, has not been evaluated in dogs suspected of hypoadrenocorticism.
In humans, the spectrum of adrenal insufficiency ranges from overt adrenal crisis to subtle dysfunction in asymptomatic patients.
Even with subtle dysfunction, patients may be at risk of developing acute adrenal insufficiency because their hypothalamic-pituitaryadrenal axis cannot react appropriately to stress. 13 
| MATERIALS AND METHODS
The Institutional Animal Care and Use Committee of Auburn University approved this study. All samples for cortisol measurement were placed into plain collection tubes and centrifuged after clotting within 1 hour of collection.
| Dogs suspected of hypoadrenocorticism
Serum was separated and stored at −20 C until analysis. Samples collected for measurement of endogenous ACTH were placed into vacutainer tubes containing EDTA. Aprotonin (Trasylol, Aprotinin bovine lung lyophilized powder (Ultrapure), Affymetrix, Inc., Cleveland, OH) was added to the blood immediately (0.1 mL aprotonin [10,000 KIU/mL] per 2 mL blood). 16 The sample then was mixed gently and centrifuged immediately. Plasma was removed immediately after centrifugation and stored in a plastic tube at −80 C until analysis.
An ACTH-stimulated serum cortisol concentration <2 μg/dL was considered diagnostic of hypoadrenocorticism, whereas an ACTHstimulated serum cortisol concentration between 2 and 5 μg/dL was considered equivocal. 4, 17, 18 Conversely, an ACTH-stimulated serum cortisol concentration >5 μg/dL excluded hypoadrenocorticism as a differential diagnosis. 4 Partial ACTH deficiency was defined as an 
| Preparation of cosyntropin
Cosyntropin was supplied as 250 μg of lyophilized powder in 2 mL vials. Each vial was reconstituted with 1.0 mL sterile saline solution to make a final concentration of 250 μg/mL in accordance with the manufacturer's directions. Unused cosyntropin remaining after reconstitution was frozen in 50 μg aliquots in plastic syringes until use or for no longer than 4 months. 19 To administer the lower dose to small dogs, the cosyntropin was diluted to concentrations of 50 μg/mL and 10 μg/mL. To achieve a 50 μg/mL dilution, the original 1.0 mL (250 μg) of reconstituted cosyntropin was added to 4.0 mL sterile saline to achieve a final volume of 5.0 mL. To achieve a 10 μg/mL dilution, the original 1.0 mL (250 μg) of reconstituted cosyntropin was added to 24 mL of sterile saline to achieve a final volume of 25 mL.
Diluted cosyntropin was stored frozen at −20 C in plastic syringes in 1 mL aliquots. 20 No cosyntropin was thawed and refrozen.
| Assay procedures
Serum cortisol concentrations were measured using a commercially available solid phase, competitive chemiluminescent enzyme immunoassay (Immulite 1000 Cortisol Assay, Siemens HealthCare Diagnostics Products, Los Angeles, CA) that has been previously validated. 21 The lower limit of analytical sensitivity is 0.5 μg/dL. For statistical purposes, results below the sensitivity of the assay were recorded as 0.3 μg/dL. Reported inter-and intra-assay coefficients of variation for the chemiluminescent enzyme immunoassay were >20% at 0.25 μg/dL, but ≤20% at values ranging from 0.5 to 25 μg/dL. 21 The manufacturer reports crossreactivity with prednisolone (49%), methylprednisolone (22%), corticosterone (8.6%), prednisone (5.9%), and negligible cross-reactivity with other steroids tested (<1%). Samples were analyzed in multiple batches and samples from each dog were run in a single batch. All samples were assayed in duplicate.
Plasma endogenous ACTH concentrations were measured using a commercially available and previously validated immunoradiometric (IRMA) assay (Scantibodies ACTH Immunoradiometric (IRMA) Assay, Scantibodies Laboratory, Inc. Santee, CA). 22 The lower limit of analytical sensitivity was 5 pg/mL. For statistical purposes, results below the sensitivity of the assay were recorded as 2.5 pg/mL. Reported intraassay and interassay coefficients of variation for the immunoradiometric assay are <15% and <19%. 22 Samples were analyzed in a single batch and all samples were assayed in duplicate.
| Statistical analyses
Statistical analysis was performed using a commercial software package (SAS/STAT 13.2, SAS Institute, Cary, NC). For all tests, significance was set at the P < .05 level.
To compare baseline cortisol serum concentrations, a paired t test was performed. Pharmacologic equivalence of the ACTH doses was tested by determining if the 90% confidence interval (CI) for the ratio of the mean ACTH-stimulated cortisol concentration in response to each dose was fully contained within the equivalence region of 80%-125% for the ratio. It was determined that in an equivalence test of means using 2 one-sided tests on data from a 2-period cross-over design, a sample size of 32 would achieve 82% power at a 5% significance level when the true ratio of the means was 1.00, the coefficient of variation on the original unlogged scale was 0.30, and the equivalence limits of the mean ratio were 0.80 and 1.25.
3 | RESULTS
| Population
Thirty-two dogs suspected of hypoadrenocorticism were enrolled.
After analysis, 1 dog was excluded because of extremely high serum cortisol concentrations, which did not allow for exact enumeration of the results and comparison of the response to both doses of cosyntropin. Of the 31 dogs included, 17 dogs were spayed female, 1 dog was an intact female, 11 dogs were neutered males, and 2 dogs were intact males. Breeds included were Labrador retriever (n = 4), Dachshund (n = 4), Australian shepherd (n = 2), Great Dane (n = 2), and Using a diagnostic cut-off of a post-ACTH serum cortisol concentration of <5 μg/dL, the interpretation of the low-dose and standard-dose tests differed in 1 dog. The post-ACTH serum cortisol concentration on the low-dose test was 3.4 μg/dL (in the equivocal range for hypoadrenocorticism), whereas the post-ACTH serum cortisol concentration on the standard-dose test was 12.3 μg/dL (not consistent with hypoadrenocorticism).
| Endogenous ACTH concentrations
The plasma endogenous ACTH concentrations ranged from 9 to 1429 pg/mL. The median plasma endogenous ACTH concentration was 21 pg/mL.
Partial ACTH deficiency was considered in 2 dogs. In the dog that had potential atypical hypoadrenocorticism with equivocal results after a standard-dose ACTH stimulation test (post-ACTH serum cortisol concentration of 3.3 μg/dL), the endogenous ACTH concentration was 73 pg/mL (reference range, 10-80 pg/mL). Glucocorticoid replacement therapy initially was prescribed, but was discontinued by the owners without adverse effect. In the patient with disparate ACTH stimulation test results, plasma endogenous ACTH concentration was 15 pg/mL. Treatment was not initiated, and results of both ACTH stimulation tests repeated 7 months after initial presentation were within the reference range.
| DISCUSSION
This study was performed to compare the results of a low-dose (1 μg/kg) ACTH stimulation test versus a standard-dose (5 μg/kg) ACTH stimulation test performed for the diagnosis of hypoadrenocorticism. Our results indicate that ACTH-stimulated serum cortisol concentrations obtained in response to both doses of ACTH were equivalent. Instead of including a patient population that consisted only of dogs proven to have hypoadrenocorticism, dogs suspected of having hypoadrenocorticism were included to simulate the population of dogs that are tested in practice. Therefore, the low-dose ACTH stimulation test can be used to confirm a diagnosis in dogs suspected of hypoadrenocorticism.
In our study population, partial ACTH deficiency was considered in 2 dogs. The first dog was a 5-year old intact male Shih Tzu initially evaluated for intermittent vomiting, inappetence and abdominal pain. Results of both ACTH stimulation tests in the presence of normal serum sodium and potassium concentrations were equivocal. The post-ACTH serum cortisol concentrations on the low-dose and standard-dose test were 3.4 and 3.3 μg/dL, respectively; the patient's plasma endogenous ACTH concentration was 73 pg/mL. In dogs with primary hypoadrenocorticism, plasma endogenous ACTH concentrations range from 200 to 5700 pg/mL as compared to a range of 5 to 9 pg/mL in dogs with secondary hypoadrenocorticism. 23 The endogenous ACTH assay utilized in the previous study is different than the assay utilized in our study, but, when the plasma endogenous ACTH concentration was <100 pg/mL, there was good agreement between the methods. 22 Given the relatively low serum cortisol concentrations in response to ACTH in conjunction with a plasma endogenous ACTH concentration of 73 pg/ml (a result inconsistent with classic primary hypoadrenocorticism), partial ACTH deficiency was considered possible. is unlikely because the dog was not critically ill at the time of testing.
Partial ACTH deficiency and subtle adrenocortical deficiency that could only be detected with a low-dose ACTH stimulation test seems unlikely given resolution of clinical signs without treatment for hypoadrenocorticism and the results of the second set of tests.
Thus, we did not find evidence of partial ACTH deficiency. However, because only 31 dogs were included, further study is necessary before drawing more definitive conclusions.
If using the lower dose, attention must be paid to a few factors.
First, the timing of collection of the sample for measurement of ACTHstimulated serum cortisol concentration is crucial. If using a dose of 1 μg/kg, the duration of peak ACTH-stimulated serum cortisol concentrations is short. The post-ACTH serum sample must be collected at exactly 60 minutes postinjection. 12, 25 Second, we only examined IV use of the low dose. Therefore, IM injection of a low dose of cosyntropin cannot be recommended based on our data. Third, cosyntropin was diluted to achieve more accurate dosing on the low-dose test for small dogs. In concentrations as low as 0.5 μg/mL, diluted Cortrosyn ® remains stable for at least 4 months when refrigerated in plastic containers. 19 Other cosyntropin products should not be diluted and stored for use, because the stability of such products is unknown. Last, given that 1 dog had discrepant results between the 2 tests, if equivocal results are obtained on a low-dose ACTH stimulation test, a second test using a standard dose should be considered for further evaluation.
In conclusion, the use of a 1 μg/kg dosage of cosyntropin is considered equivalent to a 5 μg/kg dose of cosyntropin for screening and diagnosing dogs with clinical signs or laboratory abnormalities consistent with hypoadrenocorticism. Additional investigation is needed to further define the potential existence of partial ACTH deficiency in veterinary medicine.
